Chronic Lymphocytic Leukemia Articles

FDA Approval Sought for Ibrutinib/Rituximab in Frontline CLL/SLL
A supplemental new drug application has been submitted to the FDA for ibrutinib (Imbruvica) for use in combination with rituximab (Rituxan) for the first-line treatment of patients ≤70 years old with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Taking CLL Therapies From Bedside to Community
Michael J. Keating, MBBS, has devoted much of his career to finding means of controlling chronic lymphocytic leukemia.
The combination of ublituximab and ibrutinib improved progression-free survival, as determined by an Independent Review Committee, compared with ibrutinib alone in patients with relapsed/refractory high-risk chronic lymphocytic leukemia.
CLL Treatment Moves Toward Combo Approaches and CAR T-Cell Therapy
William G. Wierda, MD, PhD, discusses the evolving treatment paradigm in chronic lymphocytic leukemia and ongoing trials looking at novel approaches.
Rituximab Sets the Pace in Changing Lymphoma Landscape
Rituximab is used ubiquitously in the treatment of B-cell lymphomas, and has set the paradigm the field has been trying to match in drug development.
James N. Gerson, MD, discusses exciting updates in mantle cell lymphoma and chronic lymphocytic leukemia and other potentially practice-changing trials on the horizon. 
Amid Explosion of Targeted Agents, FCR Retains a Role in CLL Paradigm
Mitchell R. Smith, MD, PhD, discusses the use of chemotherapy versus targeted therapy in patients with newly diagnosed and relapsed/refractory chronic lymphocytic leukemia.
Breakthrough Therapies Enrich Evolving CLL Paradigm
Herbert A. Eradat, MD, explains how insight into the pathogenesis of chronic lymphocytic leukemia is leading to novel treatment strategies and shed light on unmet needs in the field.
Secondary Cancer Risk Remains an Unresolved Issue in CLL
David Bond, MD, addresses the ongoing challenge of second primary neoplasia in chronic lymphocytic leukemia.
Novel Combos Are Shaking Up the CLL Landscape
The rise of oral targeted therapies and novel combinations is transforming the paradigm for the frontline treatment of patients with chronic lymphocytic leukemia regardless of age, and ongoing phase III trials are likely to generate more modifications. 
Publication Bottom Border
Border Publication